The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: Current clinical trials

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The Gynecologic Oncology Group's role in developing and evaluating vital research hypotheses for women with cancer of the uterine cervix cannot be understated, as methodical and interpretable conclusions from its many clinical studies have defined, supported and driven the standard of care in several avenues of clinical care. The focus of this presentation was to review for an international audience the principle structure, underlying hypotheses and historical progress in the investigation of chemotherapy options for women identified with recurrent cervix cancer. While the impact of phase II research queues were presented, the primary focus was to review the pivotal randomized trial which now define practice standards for these women.

Original languageEnglish (US)
JournalGynecologic oncology
Volume110
Issue number3 SUPPL.2
DOIs
StatePublished - Sep 1 2008

Fingerprint

Uterine Cervical Neoplasms
Clinical Trials
Standard of Care
Research
Therapeutics
Drug Therapy
Clinical Studies

Keywords

  • Cisplatin
  • Paclitaxel
  • Phase I
  • Phase II
  • Phase III clinical studies
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer : Current clinical trials. / Coleman, Robert.

In: Gynecologic oncology, Vol. 110, No. 3 SUPPL.2, 01.09.2008.

Research output: Contribution to journalArticle

@article{3a4c75934a754812910fe5aa8194879c,
title = "The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: Current clinical trials",
abstract = "The Gynecologic Oncology Group's role in developing and evaluating vital research hypotheses for women with cancer of the uterine cervix cannot be understated, as methodical and interpretable conclusions from its many clinical studies have defined, supported and driven the standard of care in several avenues of clinical care. The focus of this presentation was to review for an international audience the principle structure, underlying hypotheses and historical progress in the investigation of chemotherapy options for women identified with recurrent cervix cancer. While the impact of phase II research queues were presented, the primary focus was to review the pivotal randomized trial which now define practice standards for these women.",
keywords = "Cisplatin, Paclitaxel, Phase I, Phase II, Phase III clinical studies, Topotecan",
author = "Robert Coleman",
year = "2008",
month = "9",
day = "1",
doi = "10.1016/j.ygyno.2008.04.017",
language = "English (US)",
volume = "110",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3 SUPPL.2",

}

TY - JOUR

T1 - The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer

T2 - Current clinical trials

AU - Coleman, Robert

PY - 2008/9/1

Y1 - 2008/9/1

N2 - The Gynecologic Oncology Group's role in developing and evaluating vital research hypotheses for women with cancer of the uterine cervix cannot be understated, as methodical and interpretable conclusions from its many clinical studies have defined, supported and driven the standard of care in several avenues of clinical care. The focus of this presentation was to review for an international audience the principle structure, underlying hypotheses and historical progress in the investigation of chemotherapy options for women identified with recurrent cervix cancer. While the impact of phase II research queues were presented, the primary focus was to review the pivotal randomized trial which now define practice standards for these women.

AB - The Gynecologic Oncology Group's role in developing and evaluating vital research hypotheses for women with cancer of the uterine cervix cannot be understated, as methodical and interpretable conclusions from its many clinical studies have defined, supported and driven the standard of care in several avenues of clinical care. The focus of this presentation was to review for an international audience the principle structure, underlying hypotheses and historical progress in the investigation of chemotherapy options for women identified with recurrent cervix cancer. While the impact of phase II research queues were presented, the primary focus was to review the pivotal randomized trial which now define practice standards for these women.

KW - Cisplatin

KW - Paclitaxel

KW - Phase I

KW - Phase II

KW - Phase III clinical studies

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=50049101436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049101436&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.04.017

DO - 10.1016/j.ygyno.2008.04.017

M3 - Article

C2 - 18584855

AN - SCOPUS:50049101436

VL - 110

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3 SUPPL.2

ER -